|

Rinzimetostat Clinical Trials

1 actively recruiting trial across 1 location

Also known as: ORIC-944

Pipeline

Phase 3: 1

Top Sponsors

  • ORIC Pharmaceuticals1

Indications

  • Metastatic Castration-resistant Prostate Cancer1
  • Cancer1

Charlotte, North Carolina1 trial

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Urology Specialists of the Carolinas - University Place

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.